change of left ventricular ejection fraction (LVEF) (DcTnI : p¼0.0874, DCKMB: p¼0.9195) after TA-TAVR was similar between tertiles of both cardiac biomarkers. Conclusions: In pts undergoing TA-TAVR in the PARTNER trial, a greater degree of cTnI or CKMB elevation was not associated with significantly higher all-cause or cardiovascular mortality rates, at 30-days and at 1 year. Moreover, the degree of myocardial injury had no impact on improvement in NYHA functional class or on LVEF recovery.
Humanitas Institute, Milan, ID
Background: It is controversial whether female sex affects mortality after transcatheter aortic valve implantation (TAVI). Post-procedural AR ! 2 is a predictor of mortality after (TAVI). Sex-differences in aortic and anatomic factors may affect postprocedural AR. The aim of this study was a) to assess sex-differences in mortality after TAVI, b) to investigate sex-differences in post-procedural AR and the interaction between female sex and AR on mortality after TAVI. Methods: This is a multicenter registry enrolling consecutive patients with symptomatic severe aortic stenosis undergoing TAVI with the CoreValve system (92.8%) or the Edwards SAPIEN valve system (7.2%). Multivariable Cox regression was performed to compute hazard ratios (HR) with 95% confidence interval (CI). Results: A total of 656 patients, median age 83 yrs, (25th-75th percentile 79-86 yrs), women (53.1%), men (46.9%) were enrolled. Body surface area (1.71 vs 1.81, p<0.001) and annulus diameter (21.5 mm vs 23 mm, p<0.001) were significantly smaller in women than in men. Procedural success was similar in women as compared to men (97.9% vs 96.7% in men, p¼0.32) . Post-procedural AR ! 2 was significantly less frequent in women than in men (20.9% vs 29.6%, p¼0.01). After a median follow-up of 372 days, all-cause mortality tended to be lower in women than in men (20.7% vs 26.6%, logrank p¼0.10), while it was significantly higher in patients with AR ! 2 than in those without (34.8% vs 19.7%, logrank P<0.001). At multivariable Cox regression post-procedural AR ! 2 (HR1.73, 95% confidence interval (CI) 1.22-2.43, p¼0.002), but not female sex (p¼0.17) was an independent predictor of allcause death. AR ! 2 was a significant predictor of all-cause death among men (HR 2.96, p<0.001), but not among women (HR 0.86, p¼0.60 ; p for interaction 0.002). Conclusions: Postprocedural AR ! 2, but not female sex, is an independent predictor of all-cause mortality at mid-term follow-up. AR ! 2 occurs less frequently among women, and its prognostic impact is restricted to men.
TCT-756
Usefulness University of Pittsburgh, Pittsburgh, PA Background: Valvuloarterial impedance (Zva) is an index assessing global left ventricular (LV) afterload that has shown to be a predictor of mortality in patients with aortic stenosis (AS). We set out to evaluate whether improvement of Zva immediately after balloon aortic valvuloplasty (BAV) can predict short term outcomes in high surgical risk patients with severe AS evaluated for TAVI.
Methods: 85 consecutive patients with severe AS underwent BAV. The prognostic effectiveness of a new Zva index ratio, defined as the ratio of the post-BAV Zva to the pre-BAV Zva (post-Zva/pre-Zva), for 6-month endpoint event was evaluated in patients not eligible for surgical valve replacement. Central systolic arterial pressure (averaged from at least 3 measurements), mean transvalvular pressure gradient and stroke volume index were obtained using invasive measurements. Results: The postZva/preZva index ratio is a good predictor for 6-month endpoint event. A cutoff value <0.85 was strongly associated with poor survival at 6 months. Zva-derived measurements were similar between both groups with postZva/preZva <0.85 and !0.85.
Conclusions: Assessment of global LV hemodynamic load before and after BAV as measured by the postZva/preZva index ratio may provide additional risk information in high risk patients with severe AS evaluated for TAVR.
TCT-757
A new transcatheter aortic valve design with enhanced durability: prototype design, fabrication and hydrodynamic testing results Background: As the application of transcatheter aortic valve (TAV) implantation moves towards intermediate or low risk patients, TAV durability will be a greater concern. Current TAVs employ thin tissue leaflets, have limited or no stent-tip deflection, and often exhibit "pinwheeled" leaflets due to abnormal deployment. These factors are known to increase stress and limit the durability of surgical pericardial valves. In this study, we present an elegant leaflet design of TAVs with chordal reinforcement (Chord-TAVs) that can mitigate leaflet stress concentrations and enhance overall valve durability. Methods: Optimal designs of Chord-TAVs were obtained through computational modeling. Chord-TAVs were fabricated from glutaraldehyde-treated thin bovine pericardium sewn onto size 23 woven nitinol stents. The leaflet strain distributions of ChordTAVs were measured from a static pressurization test. The Chord-TAVs were then subjected to hydrodynamics and accelerated wear testing (AWT) per ISO-5840:2005. Results: Optimized Chord-TAVs reduced simulated leaflet peak stress by 43% compared to a chordless TAV and was comparable to simulated surgical CEP stress. Chord-TAV strain distribution was up to 42% lower than for fabricated chordless valves. Chord-TAVs exhibited satisfactory hydrodynamics for size 23 valves. Initial AWT testing data indicated that strain reduction continues following cyclic loading (Fig.1) .
Conclusions: Chord-TAVs with chordal reinforcement provided structural support that greatly reduced leaflet stress and strain. Such reduction will improve valve performance and overall valve durability.
TCT-758
Age Background: A strong component of predicted mortality in scoring systems is advanced age, however, outcomes data in nonagenarians (age >90 years) is lacking. We evaluated surgical outcomes after aortic valve replacement (AVR) in nonagenarians at our institution over an 11-year period. Methods: Demographics, procedural details, and in-hospital outcomes were retrospectively analyzed on 119 patients with severe aortic stenosis (AS) who underwent AVR or AVR+concomitant surgery between 2001 and 2012. Mean duration of follow-up was 915AE832 days. Results: The average age was 91.7AE1.9 years (range 90-97) and mean STS score was 8.9AE5.7. Over 98% of patients met echocardiographic criteria for severe AS (mean gradient 45.0AE16.1 mmHg, aortic valve area 0.66AE0.2 cm2), had an ejection fraction of 49.8AE11.8%, and 47% underwent an isolated AVR. Though average length of stay was longer than expected, rates of prolonged ventilation (16.8%), new atrial fibrillation (43.7%), stroke (0.8%), and renal failure (5.9%) were acceptable. Three patients (2.5%) required reoperation for bleeding. Overall 30 day or in-hospital mortality was 7.6%, and multivariate predictors of mortality at 1 years included prior myocardial infarction (HR 2.79, 95% CI: 1.21-6.45, p¼0.016), obstructive lung disease (HR 3.90, 95% CI: 1.66-9.15, p¼0.025), and diabetes (HR 2.77, 95% CI: 1.08-7.07, p¼0.033). Observed mortality at 30 days was lower than expected (observed/expected¼0.85).
Conclusions: Excellent procedural and long-term outcomes can be achieved in nonagenarians, and age alone should not be a contraindication for valve replacement in select populations. This sample cohort validates the feasibility of a primary operative strategy in elderly patients with AS and acceptable risk profiles.
TCT-759
Correlates University of British Columbia, Vancouver, BC Background: The incidence of transcatheter heart valve (THV) device malposition is higher during aortic valve-in-valve implantation (VinV). We aimed to evaluate for correlates for this complication. Methods: Aortic VinV procedures included in the Global Valve-in-Valve Registry were investigated (459 procedures, 246 Edwards SAPIEN and 213 CoreValve). Results: THV device malposition occurred in 50 cases (10.9%) resulting in attempted device retreival (10.3% of CoreValve implantations) and second THV device implantation (7.5% CoreValve vs. 4.1% Edwards SAPIEN, p¼0.052). Device malposition was more common during CoreValve VinV procedures(16.4% vs. 6.1%, Edwards SAPIEN, p¼0.0004). In Edwards SAPIEN VinV procedures there was no difference in malposition rate between transfemoral and transapical procedures (4.1% vs. 7%, p¼0.39). Device malposition was more common in procedures performed early in the learning-curve (14.4% vs. 9% after the seventh case per center, p¼0.046), with regurgitant bioprostheses (13.3% vs. 7.2% in bioprostheses with isolated stenosis, p¼0.04) and with stentless and Mosaic stented valves (16.1%,14.0% vs. 9.0% in non-Mosaic stented valves, p¼0.04). Conclusions: Device malposition is common during aortic VinV procedures and may result implantation of a second THV device. Malposition was more common when performed early in the learning curve, with CoreValve VinV procedures and with regurgitant, stentless and Mosaic bioprostheses. Weill-Cornell Medical College and Methodist DeBakey Heart Center, Houston, TX Background: Low-Flow Low-Gradient (LF-LG) or "Paradoxical Aortic Stenosis" is a rarely encountered clinical entity with limited data on clinical outcomes after surgical (SAVR) or trans-catheter aortic valve (TAVI) replacement. We conducted a meta-analysis of all the studies comparing all-cause mortality after aortic valve replacement in LF-LG AS in comparison to medical therapy alone. Methods: A thorough PubMed (time-unlimited till 06/01/2013) search revealed 5 studies comparing TAVI/SAVR outcomes in LF-LG aortic stenosis (mean gradient <40mmHg; stroke volume index <35ml/m2). Primary clinical endpoint was all-cause mortality at 2 year follow-up. Odds ratio (OR) and confidence interval (CI) were estimated using the random effects model. Results: A total of 607 patients (SAVR/TAVI 263; medical therapy 344) were included in the analysis. Baseline characteristics of these patients in valve replacement and medical therapy arms were comparable. At 2-year follow-up, SAVR/TAVI was associated with lower all-cause mortality (24.3% vs. 55.8%; OR 0.23; 95% CI 0.15 -0.36). This corresponds to an absolute risk reduction of 31.5% and a Number Needed to Treat 3.55 to save one life. Re-operation for bleeding, n (%) 3 (2.5%)
30-day or in-hospital mortality, n (%) 9 (7.6%) www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
